SpringWorks Therapeutics(SWTX) - 2024 Q1 - Quarterly Results

– Achieved $21.0 million in OGSIVEO (nirogacestat) net product revenue in the first quarter – ® – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – Exhibit 99.1 SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at ...